精神障碍中的PET成像
本文综述了PET在精神障碍研究中的应用,涵盖精神分裂症、心境障碍、孤独症谱系障碍、注意缺陷多动障碍及成瘾等,涉及脑代谢、神经递质、受体结合、突触密度和神经炎症等靶点,并讨论了其在鉴别诊断和治疗反应监测中的潜在价值及临床推广的障碍。
要点
- 18F-FDG-PET显示精神分裂症和重性抑郁障碍存在前额叶代谢减低。
- 精神分裂症与纹状体多巴胺合成能力及释放增加相关,抑郁障碍则显示5-羟色胺转运体结合减低。
- PET可辅助鉴别原发性精神障碍与神经退行性疾病,并用于预测和监测治疗反应。
核心结论
- PET在精准精神病学中具有变革性作用,作者主张扩大其研究和临床应用。
研究设计与样本
- 本文为综合性综述,汇总了PET在精神障碍中应用的现有证据。
主要发现
- 18F-FDG-PET一致显示区域性代谢异常,最突出的是精神分裂症和重性抑郁障碍的前额叶代谢减低。
- 功能FDG-PET(fPET)近期实现了高时间分辨率的动态代谢成像,可评估刺激诱导的神经元活动变化。
- 受体特异性PET示踪剂揭示了多巴胺能、5-羟色胺能、谷氨酸能和GABA能系统在精神疾病谱中的失调。
- 精神分裂症与纹状体多巴胺合成能力及多巴胺释放增加、额边缘连接破坏相关;抑郁障碍显示5-羟色胺转运体结合减低和mGluR5可用性降低。
- PET还揭示了神经炎症特征(如TSPO结合改变)以及早期精神病中经SV2A示踪剂显示的突触密度减低。
临床怎么用
- PET成像有助于鉴别原发性精神障碍与神经退行性疾病(包括行为变异型额颞叶痴呆),通过检测疾病特异性代谢模式支持生物标志物指导的诊断。
- PET已用于预测和监测药物及神经调控干预(包括抗抑郁药、电休克治疗和认知行为治疗)的治疗反应。
局限性
- PET在精神病学中的广泛临床整合仍受限于高成本、可及性障碍以及需要标准化的采集和解读方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Positron emission tomography (PET) has emerged as a pivotal imaging modality in the investigation of psychiatric disorders, enabling in vivo assessment of regional cerebral metabolism, neurotransmitter dynamics, receptor binding, synaptic density, and neuroinflammation. This comprehensive review synthesizes current evidence on the utility of PET imaging in elucidating the pathophysiology of major psychiatric conditions-including schizophrenia, mood disorders, autism spectrum disorder, attention-deficit/hyperactivity disorder, and addiction and its potential in clinical decision-making. 18F-FDG-PET has consistently demonstrated regional metabolic abnormalities, most notably prefrontal hypometabolism in schizophrenia and major depressive disorder, with implications for negative symptomatology, cognitive dysfunction, and treatment resistance. Functional FDG-PET (fPET) has recently enabled dynamic metabolic mapping with high temporal resolution, allowing the evaluation of stimulus-induced changes in neuronal activity. Receptor-specific PET tracers have provided further insights into dopaminergic, serotonergic, glutamatergic, and GABAergic dysregulation across psychiatric spectra. Notably, schizophrenia is associated with a increased striatal dopamine (DA) synthesis capacity and DA release, and disrupted frontolimbic connectivity, while depression shows reduced serotonergic transporter binding and lower mGluR5 availability, supporting neurotransmitter system-based subtyping. PET imaging has also revealed neuroinflammatory signatures, such as altered TSPO binding, as well as synaptic density reductions via SV2A tracers in early psychosis, emphasizing shared neurobiological underpinnings and disease progression markers. In pediatric and neurodevelopmental disorders, including ASD, PET and multimodal approaches have contributed to identifying heterogeneous neurochemical phenotypes, linking abnormal glucose metabolism and receptor availability to specific behavioral domains. Clinically, PET imaging aids in the differential diagnosis of primary psychiatric disorders from neurodegenerative conditions, including behavioral variant frontotemporal dementia (bvFTD), by detecting disease-specific metabolic patterns and supporting biomarker-informed diagnostics. Furthermore, PET has been employed to predict and monitor treatment response across pharmacological and neuromodulatory interventions, including antidepressants, electroconvulsive therapy (ECT), and cognitive behavioral therapy (CBT), enabling strides toward personalized psychiatric care. Despite its promise, widespread clinical integration of PET in psychiatry remains limited by high cost, accessibility barriers, and the need for standardized acquisition and interpretation protocols. Ongoing advancements in radiopharmaceutical development, artificial intelligence, and normative imaging databases are expected to facilitate the incorporation of PET into routine psychiatric assessment and therapeutic planning. This review underscores the transformative role of PET in precision psychiatry and advocates for its expanded research and clinical application.
引用
- Ferrando R, Hernandes D, Ghini BG, et al. PET Imaging in Psychiatric Disorders. Semin Nucl Med. 2025. PMID: 40544068. doi:10.1053/j.semnuclmed.2025.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。